Cargando…

Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies

Many challenges exist in the precise diagnosis and clinical management of secondary progressive multiple sclerosis (SPMS) because of the lack of definitive clinical, imaging, immunologic, or pathologic criteria that demarcate the transition from relapsing-remitting MS to SPMS. This review provides a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ziemssen, Tjalf, Bhan, Virender, Chataway, Jeremy, Chitnis, Tanuja, Campbell Cree, Bruce Anthony, Havrdova, Eva Kubala, Kappos, Ludwig, Labauge, Pierre, Miller, Aaron, Nakahara, Jin, Oreja-Guevara, Celia, Palace, Jacqueline, Singer, Barry, Trojano, Maria, Patil, Ashwini, Rauser, Benedict, Hach, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682625/ https://www.ncbi.nlm.nih.gov/pubmed/36414428 http://dx.doi.org/10.1212/NXI.0000000000200064

Ejemplares similares

Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Improving patient–physician dialog: commentary on the results of the MS Choices survey
por: Lugaresi, Alessandra, et al.
Publicado: (2012)

Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC)
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
por: Coles, Alasdair J, et al.
Publicado: (2021)

Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2023)

Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
por: Centonze, Diego, et al.
Publicado: (2021)

Secondary Progressive Multiple Sclerosis: New Insights
por: Cree, Bruce A.C., et al.
Publicado: (2021)

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
por: Coles, Alasdair J., et al.
Publicado: (2023)

Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting
por: Albrecht, Philipp, et al.
Publicado: (2018)

Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies
por: Bertolotto, Antonio, et al.
Publicado: (2020)

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

The Investigation of the Cardiovascular and Sudomotor Autonomic Nervous System—A Review
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Why Cognitive–Cognitive Dual-Task Testing Assessment Should Be Implemented in Studies on Multiple Sclerosis and in Regular Clinical Practice
por: Beste, Christian, et al.
Publicado: (2020)

Digital Innovation in Multiple Sclerosis Management
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

The Role of CD4 T Cells in the Pathogenesis of Multiple Sclerosis
por: Chitnis, Tanuja
Publicado: (2007)

Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis
por: Healy, Brian C., et al.
Publicado: (2013)

A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Real-Life Outcome in Multiple Sclerosis in the Czech Republic
por: Kobelt, Gisela, et al.
Publicado: (2019)

Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis
por: Filippi, Massimo, et al.
Publicado: (2021)

Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetate
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

The Change of Fingolimod Patient Profiles over Time: A Descriptive Analysis of Two Non-Interventional Studies PANGAEA and PANGAEA 2.0
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Future MS care: a consensus statement of the MS in the 21st Century Steering Group
por: Rieckmann, Peter, et al.
Publicado: (2012)

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial
por: Coles, Alasdair J., et al.
Publicado: (2021)

Interdisziplinäre Kommunikation: Augenarztbriefe an diabetologische Schwerpunktpraxen (DSP)
por: Stock, Lydia, et al.
Publicado: (2020)

Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study
por: Butzkueven, Helmut, et al.
Publicado: (2022)

The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Fatigue and Sleep in Multiple Sclerosis Patients: A Comparison of Self-Report and Performance-Based Measures
por: Paucke, Madlen, et al.
Publicado: (2018)

The importance of collecting structured clinical information on multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Spectral Analysis of Heart Rate Variability: Time Window Matters
por: Li, Kai, et al.
Publicado: (2019)

Molecular biomarkers in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety
por: Moser, Tobias, et al.
Publicado: (2022)

Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease
por: Corbali, Osman, et al.
Publicado: (2023)

The potential of serum neurofilament as biomarker for multiple sclerosis
por: Bittner, Stefan, et al.
Publicado: (2021)

Steroid Sulfation in Neurodegenerative Diseases
por: Vitku, Jana, et al.
Publicado: (2022)

Patient-reported outcome measures in MS: Do development processes and patient involvement support valid quantification of clinically important variables?
por: Bharadia, Trishna, et al.
Publicado: (2022)

Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE
por: Cohan, Stanley, et al.
Publicado: (2017)

Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol
por: Vormfelde, Stefan Viktor, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bn9g7gjc92kmchuojm6q1jdfsv